A citation-based method for searching scientific literature

M Xing. Endocr Relat Cancer 2005
Times Cited: 897







List of co-cited articles
754 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
Bryan R Haugen, Erik K Alexander, Keith C Bible, Gerard M Doherty, Susan J Mandel, Yuri E Nikiforov, Furio Pacini, Gregory W Randolph, Anna M Sawka, Martin Schlumberger,[...]. Thyroid 2016
37



Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.
Mingzhao Xing, Ali S Alzahrani, Kathryn A Carson, Young Kee Shong, Tae Yong Kim, David Viola, Rossella Elisei, Bela Bendlová, Linwah Yip, Caterina Mian,[...]. J Clin Oncol 2015
296
20

Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.
Mingzhao Xing, Ali S Alzahrani, Kathryn A Carson, David Viola, Rossella Elisei, Bela Bendlova, Linwah Yip, Caterina Mian, Federica Vianello, R Michael Tuttle,[...]. JAMA 2013
543
18

Molecular genetics and diagnosis of thyroid cancer.
Yuri E Nikiforov, Marina N Nikiforova. Nat Rev Endocrinol 2011
568
17

BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.
Marina N Nikiforova, Edna T Kimura, Manoj Gandhi, Paul W Biddinger, Jeffrey A Knauf, Fulvio Basolo, Zhaowen Zhu, Riccardo Giannini, Giuliana Salvatore, Alfredo Fusco,[...]. J Clin Endocrinol Metab 2003
746
16


BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.
Mingzhao Xing, Rengyun Liu, Xiaoli Liu, Avaniyapuram Kannan Murugan, Guangwu Zhu, Martha A Zeiger, Sara Pai, Justin Bishop. J Clin Oncol 2014
382
16

Highly prevalent TERT promoter mutations in aggressive thyroid cancers.
Xiaoli Liu, Justin Bishop, Yuan Shan, Sara Pai, Dingxie Liu, Avaniyapuram Kannan Murugan, Hui Sun, Adel K El-Naggar, Mingzhao Xing. Endocr Relat Cancer 2013
363
16

Mutations of the BRAF gene in human cancer.
Helen Davies, Graham R Bignell, Charles Cox, Philip Stephens, Sarah Edkins, Sheila Clegg, Jon Teague, Hayley Woffendin, Mathew J Garnett, William Bottomley,[...]. Nature 2002
16


TERT promoter mutations in thyroid cancer.
Rengyun Liu, Mingzhao Xing. Endocr Relat Cancer 2016
178
15

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
Mingzhao Xing, William H Westra, Ralph P Tufano, Yoram Cohen, Eli Rosenbaum, Kerry J Rhoden, Kathryn A Carson, Vasily Vasko, Alexandr Larin, Giovanni Tallini,[...]. J Clin Endocrinol Metab 2005
690
14

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
Iñigo Landa, Tihana Ibrahimpasic, Laura Boucai, Rileen Sinha, Jeffrey A Knauf, Ronak H Shah, Snjezana Dogan, Julio C Ricarte-Filho, Gnana P Krishnamoorthy, Bin Xu,[...]. J Clin Invest 2016
464
13

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.
David S Cooper, Gerard M Doherty, Bryan R Haugen, Richard T Kloos, Stephanie L Lee, Susan J Mandel, Ernest L Mazzaferri, Bryan McIver, Furio Pacini, Martin Schlumberger,[...]. Thyroid 2009
13

TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.
Miguel Melo, Adriana Gaspar da Rocha, João Vinagre, Rui Batista, Joana Peixoto, Catarina Tavares, Ricardo Celestino, Ana Almeida, Catarina Salgado, Catarina Eloy,[...]. J Clin Endocrinol Metab 2014
303
12

Progress in molecular-based management of differentiated thyroid cancer.
Mingzhao Xing, Bryan R Haugen, Martin Schlumberger. Lancet 2013
325
12

TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.
Xiaoli Liu, Shen Qu, Rengyun Liu, Chunjun Sheng, Xiaoguang Shi, Guangwu Zhu, Avaniyapuram Kannan Murugan, Haixia Guan, Hongyu Yu, Yangang Wang,[...]. J Clin Endocrinol Metab 2014
180
11

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Martin Schlumberger, Makoto Tahara, Lori J Wirth, Bruce Robinson, Marcia S Brose, Rossella Elisei, Mouhammed Amir Habra, Kate Newbold, Manisha H Shah, Ana O Hoff,[...]. N Engl J Med 2015
820
11

RAS mutations in thyroid cancer.
Gina M Howell, Steven P Hodak, Linwah Yip. Oncologist 2013
103
10

Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
Iñigo Landa, Ian Ganly, Timothy A Chan, Norisato Mitsutake, Michiko Matsuse, Tihana Ibrahimpasic, Ronald A Ghossein, James A Fagin. J Clin Endocrinol Metab 2013
258
10



BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.
Ralph P Tufano, Gilberto V Teixeira, Justin Bishop, Kathryn A Carson, Mingzhao Xing. Medicine (Baltimore) 2012
198
9

BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.
Paula Soares, Vítor Trovisco, Ana Sofia Rocha, Jorge Lima, Patrícia Castro, Ana Preto, Valdemar Máximo, Tiago Botelho, Raquel Seruca, Manuel Sobrinho-Simões. Oncogene 2003
489
9

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
Vivek Subbiah, Robert J Kreitman, Zev A Wainberg, Jae Yong Cho, Jan H M Schellens, Jean Charles Soria, Patrick Y Wen, Christoph Zielinski, Maria E Cabanillas, Gladys Urbanowitz,[...]. J Clin Oncol 2018
267
9

BRAF mutation in papillary thyroid carcinoma.
Yoram Cohen, Mingzhao Xing, Elizabeth Mambo, Zhongmin Guo, Guogun Wu, Barry Trink, Uziel Beller, William H Westra, Paul W Ladenson, David Sidransky. J Natl Cancer Inst 2003
618
9

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
Marcia S Brose, Christopher M Nutting, Barbara Jarzab, Rossella Elisei, Salvatore Siena, Lars Bastholt, Christelle de la Fouchardiere, Furio Pacini, Ralf Paschke, Young Kee Shong,[...]. Lancet 2014
732
9

The prevalence and prognostic value of BRAF mutation in thyroid cancer.
Electron Kebebew, Julie Weng, Juergen Bauer, Gustavo Ranvier, Orlo H Clark, Quan-Yang Duh, Daniel Shibru, Boris Bastian, Ann Griffin. Ann Surg 2007
316
9

Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013.
Hyeyeun Lim, Susan S Devesa, Julie A Sosa, David Check, Cari M Kitahara. JAMA 2017
732
8

Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.
Julio C Ricarte-Filho, Mabel Ryder, Dhananjay A Chitale, Michael Rivera, Adriana Heguy, Marc Ladanyi, Manickam Janakiraman, David Solit, Jeffrey A Knauf, R Michael Tuttle,[...]. Cancer Res 2009
352
8

RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.
Marina N Nikiforova, Roy A Lynch, Paul W Biddinger, Erik K Alexander, Gerald W Dorn, Giovanni Tallini, Todd G Kroll, Yuri E Nikiforov. J Clin Endocrinol Metab 2003
472
8

Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas.
Adebowale J Adeniran, Zhaowen Zhu, Manoj Gandhi, David L Steward, James P Fidler, Thomas J Giordano, Paul W Biddinger, Yuri E Nikiforov. Am J Surg Pathol 2006
336
8

Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers.
Hiroyuki Namba, Masahiro Nakashima, Tomayoshi Hayashi, Naomi Hayashida, Shigeto Maeda, Tatiana I Rogounovitch, Akira Ohtsuru, Vladimir A Saenko, Takashi Kanematsu, Shunichi Yamashita. J Clin Endocrinol Metab 2003
424
8

Biologic and Clinical Perspectives on Thyroid Cancer.
James A Fagin, Samuel A Wells. N Engl J Med 2016
313
8

Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.
Zhi Liu, Peng Hou, Meiju Ji, Haixia Guan, Kimberly Studeman, Kirk Jensen, Vasily Vasko, Adel K El-Naggar, Mingzhao Xing. J Clin Endocrinol Metab 2008
273
8

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
Rossella Elisei, Clara Ugolini, David Viola, Cristiana Lupi, Agnese Biagini, Riccardo Giannini, Cristina Romei, Paolo Miccoli, Aldo Pinchera, Fulvio Basolo. J Clin Endocrinol Metab 2008
359
7


Highly recurrent TERT promoter mutations in human melanoma.
Franklin W Huang, Eran Hodis, Mary Jue Xu, Gregory V Kryukov, Lynda Chin, Levi A Garraway. Science 2013
6

BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients.
Langping Jin, Endong Chen, Siyang Dong, Yefeng Cai, Xiangjian Zhang, Yili Zhou, Ruichao Zeng, Fan Yang, Chuanmeng Pan, Yehuan Liu,[...]. Oncotarget 2016
74
8

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
Alan L Ho, Ravinder K Grewal, Rebecca Leboeuf, Eric J Sherman, David G Pfister, Desiree Deandreis, Keith S Pentlow, Pat B Zanzonico, Sofia Haque, Somali Gavane,[...]. N Engl J Med 2013
413
6

Patient Age-Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer.
Xiaopei Shen, Guangwu Zhu, Rengyun Liu, David Viola, Rossella Elisei, Efisio Puxeddu, Laura Fugazzola, Carla Colombo, Barbara Jarzab, Agnieszka Czarniecka,[...]. J Clin Oncol 2018
50
12

ENDOCRINE TUMOURS: Genetic predictors of thyroid cancer outcome.
Catarina Tavares, Miguel Melo, José Manuel Cameselle-Teijeiro, Paula Soares, Manuel Sobrinho-Simões. Eur J Endocrinol 2016
44
13

BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism.
C Durante, E Puxeddu, E Ferretti, R Morisi, S Moretti, R Bruno, F Barbi, N Avenia, A Scipioni, A Verrienti,[...]. J Clin Endocrinol Metab 2007
254
6

BRAF mutation in papillary thyroid carcinoma: predictive value for long-term prognosis and radioiodine sensitivity.
A Zoghlami, F Roussel, J-C Sabourin, J-M Kuhn, J-P Marie, D Dehesdin, O Choussy. Eur Ann Otorhinolaryngol Head Neck Dis 2014
17
35

Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.
Lola Rahib, Benjamin D Smith, Rhonda Aizenberg, Allison B Rosenzweig, Julie M Fleshman, Lynn M Matrisian. Cancer Res 2014
6

BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients.
Yasuhiro Ito, Hiroshi Yoshida, Rie Maruo, Shinji Morita, Toru Takano, Mitsuyoshi Hirokawa, Tomonori Yabuta, Mitsuhiro Fukushima, Hiroyuki Inoue, Chisato Tomoda,[...]. Endocr J 2009
185
6

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
Marcia S Brose, Maria E Cabanillas, Ezra E W Cohen, Lori J Wirth, Todd Riehl, Huibin Yue, Steven I Sherman, Eric J Sherman. Lancet Oncol 2016
142
6

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
Keith T Flaherty, Jeffery R Infante, Adil Daud, Rene Gonzalez, Richard F Kefford, Jeffrey Sosman, Omid Hamid, Lynn Schuchter, Jonathan Cebon, Nageatte Ibrahim,[...]. N Engl J Med 2012
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.